Tyra Biosciences, Inc. Debt Securities, Available-for-sale, Unrealized Gain
Tyra Biosciences, Inc. (TYRA) reported Debt Securities, Available-for-sale, Unrealized Gain of $231.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Income Statement › Other Income
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain · last filed 2026-05-13
- Tyra Biosciences, Inc. debt securities, available-for-sale, unrealized gain for the quarter ending 2026-03-31 was $231.00K, a 66.95% decline year-over-year.
- Tyra Biosciences, Inc. debt securities, available-for-sale, unrealized gain for the quarter ending 2025-12-31 was -$68.00K.
- Tyra Biosciences, Inc. debt securities, available-for-sale, unrealized gain for the quarter ending 2025-09-30 was $9.00K, a 99.46% decline year-over-year.
- Tyra Biosciences, Inc. debt securities, available-for-sale, unrealized gain for the quarter ending 2025-06-30 was -$247.00K, a 12450.00% decline year-over-year.
- Tyra Biosciences, Inc. debt securities, available-for-sale, unrealized gain for fiscal 2024 was $797.00K, a 107.55% increase from fiscal 2023.
- Tyra Biosciences, Inc. debt securities, available-for-sale, unrealized gain for fiscal 2023 was $384.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain 3 month | Debt Securities, Available-for-sale, Unrealized Gain 6 month | Debt Securities, Available-for-sale, Unrealized Gain 9 month | Debt Securities, Available-for-sale, Unrealized Gain 12 month |
|---|---|---|---|---|
| 2026-03-31 | $231.00K 10-Q · filed 2026-05-13 | $163.00K derived: sum of 2 quarters · filed 2026-05-13 | $172.00K derived: sum of 3 quarters · filed 2026-05-13 | -$75.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | -$68.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2026-05-13 | -$59.00K derived: sum of 2 quarters · filed 2026-05-13 | -$306.00K derived: sum of 3 quarters · filed 2026-05-13 | $393.00K 10-Q · filed 2026-05-13 |
| 2025-09-30 | $9.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$238.00K derived: sum of 2 quarters · filed 2025-11-05 | $461.00K 10-Q · filed 2025-11-05 | -$495.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2025-06-30 | -$247.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $452.00K 10-Q · filed 2025-08-14 | -$504.00K derived: sum of 3 quarters · filed 2026-03-02 | $1.18M derived: sum of 4 quarters · filed 2026-03-02 |
| 2025-03-31 | $699.00K 10-Q · filed 2025-05-08 | -$257.00K derived: sum of 2 quarters · filed 2026-03-02 | $1.42M derived: sum of 3 quarters · filed 2026-03-02 | $1.43M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-12-31 | -$956.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $725.00K derived: sum of 2 quarters · filed 2026-03-02 | $727.00K derived: sum of 3 quarters · filed 2026-03-02 | $797.00K 10-K · filed 2026-03-02 |
| 2024-09-30 | $1.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.68M derived: sum of 2 quarters · filed 2024-11-07 | $1.75M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $72.00K 10-Q · filed 2024-08-07 | ||
| 2024-03-31 | $70.00K 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $384.00K 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |